Google’s parent company Alphabet is diving into the drug discovery game with an artificial intelligence company built on the protein-folding simulation successes achieved at DeepMind. The new Isomorphic Laboratories aims to deliver an “AI-first approach” for tackling biopharma research, with the goal of serving as a commercial partner to drugmakers and figuring out how medicines …
A patient dosed with Allogene’s off the shelf CAR-T therapy for cancer developed “chromosomal abnormalities” prompting the FDA to suspend the clinical trial while it investigates the event. The therapy, ALLO-501A was applied to a patient with B-cell follicular lymphoma. The patient subsequently lost the ability to produce sufficient blood cells. Read more here: https://www.statnews.com/2021/10/07/fda-halts-allogene-blood-cancer-trials-after-patient-found-to-have-chromosomal-abnormality/?utm_source=STAT+Newsletters&utm_campaign=593893c461-RO_COPY_04&utm_medium=email&utm_term=0_8cab1d7961-593893c461-151602985
The WHO recommendation is based on the results from an ongoing malaria vaccine pilot programme in three African nations. n a major medical breakthrough that is set to have a global impact, the World Health Organisation (WHO) has recommended the world’s first vaccine against malaria. The UN body has recommended the use of the RTS,S …
Explained: What is Mosquirix, the groundbreaking vaccine against malaria Read More »
By Sal Daher, CFA Vedanta Biosciences announced October 5th, 2021 that its experimental therapy VE303 reduces the likelihood of recurrence of C. diff. by more than 80%. BARDA exercises $23.8 million to fund Phase 3 clinical trials starting in 2022. Heres a link to the press release: https://www.businesswire.com/news/home/20211005005154/en/PureTech-Founded-Entity-Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA
High-dose VE303 in Phase 2 trial achieved primary endpoint, with 31.7% absolute risk reduction in rate of recurrence (or a greater than 80% reduction in the odds of a recurrence) at 8 weeks when compared with placebo Represents most advanced clinical trial of a rationally defined bacterial consortium candidate BARDA exercises $23.8 million option to …
This advertisement has not loaded yet, but your article continues below. The effectiveness of the Pfizer Inc /BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47% from 88% six…
WATERTOWN, Mass.–(BUSINESS WIRE)–Oct 4, 2021–
BioNTech CEO Says New Covid Vaccines Will Be Needed in 2022: FT
by Sal Daher, CFA Daphne Zohar is pioneering a distinctive approach to innovation in biotech that does not attract enough attention. It involves unusual openness to new ideas coupled with disciplined vetting of the ideas’ technical and commercial possibilities. She also has keen eye for talent. The results are astonishing. I know this first hand …
This advertisement has not loaded yet, but your article continues below. The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate…
